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Lack of Cytoplasmic ERK Activation Is an
Independent Adverse Prognostic Factor in Primary
Cutaneous Melanoma
Braslav Jovanovic1, Doris Kro¨ckel1, Diana Linden1, Bo Nilsson1, Suzanne Egyhazi1 and Johan Hansson1
The aim of this study was to estimate the impact on survival of NRAS and BRAF mutations and activation of Akt
and extracellular signal-regulated kinase (ERK) in primary melanomas. A cohort of 57 primary cutaneous T1–2
melanoma tumors was analyzed. Mutation frequency for both genes was 61% (NRAS 26% and BRAF 39%). In a
univariate analysis, shorter overall survival was associated with the presence of ulceration (P¼ 0.001) and BRAF
exon 15 mutations (P¼ 0.005) as well as the absence of nuclear activation of Akt (P¼ 0.022) and of cytoplasmic
activation of ERK (P¼ 0.003). Unexpectedly, ulceration was a significant adverse prognostic factor only in
melanomas with BRAF mutations, whereas there was no effect of ulceration on overall survival in tumors with
wild-type BRAF. A multivariate analysis showed that significant independent adverse survival prognostic
markers were absence of cytoplasmic activation of ERK (P¼ 0.007) and ulceration (P¼ 0.008), whereas BRAF exon
15 mutation status showed a nonsignificant trend (P¼ 0.066). The absence of cytoplasmic ERK activation in poor
prognosis T1–2 melanomas may be associated with activation of some other uncharacterized pathway leading to
tumor progression and adverse outcome. Immunohistochemical analysis of cytoplasmic phosphorylated ERK
could be used as a prognostic marker in primary melanomas if confirmed in another data set.
Journal of Investigative Dermatology (2008) 128, 2696–2704; doi:10.1038/jid.2008.134; published online 29 May 2008
INTRODUCTION
Melanoma thickness and histopathological ulceration are the
main prognostic markers in the current TNM classification of
malignant tumors regarding tumor (T) criteria (Balch et al.,
2001a, b). Although prognosis of melanomas treated by
surgical excision, with thickness equal or less than 1.5mm,
is generally good (Morton et al., 1993; Buttner et al., 1995;
MacKie et al., 1995; Schuchter et al., 1996; Stang et al.,
2001; Balch et al., 2001b; Averbook et al., 2002), there is a
subset of patients who have a worse survival and for whom
identification of additional prognostic markers are needed.
There is increasing evidence that activation of the
Ras–Raf–mitogen-activated protein kinase/extracellular signal-
regulated kinase (ERK) kinase (MEK)–ERK pathway is asso-
ciated with melanoma development. Previous studies showed
that 5–36% of primary melanomas have NRAS mutations
(Omholt et al., 2002; Dong et al., 2003; Kumar et al., 2003b),
whereas 25–80% harbor BRAF mutations (Davies et al.,
2002; Dong et al., 2003; Kumar et al., 2003b; Omholt et al.,
2003; Rodolfo et al., 2004; Shinozaki et al., 2004; Goel et al.,
2006). The most common alterations of the NRAS gene are in
codon 61 of exon 2 (Q61K or Q61R), with a small subset
of mutations observed in codons 12 and 13 of the first exon
(Omholt et al., 2002). Up to 90% of activating BRAF
mutations in melanoma are identified in codon 600 of exon
15, mainly V600E, with an additional ‘‘hot-spot’’ at exon 11
(Thomas, 2006). Published data also show that mutations in
these genes are almost always mutually exclusive, and
mutation frequencies in primary melanomas do not seem
to correlate with overall survival (Houben et al., 2004;
Shinozaki et al., 2004). Moreover, ERK activation has been
reported in 54–100% of primary melanomas (Cohen et al.,
2002; Jorgensen et al., 2003; Zhuang et al., 2005; Uribe
et al., 2006), with one report showing that 93% of primary
melanomas with codon 600 BRAF mutations had activated
ERK (Uribe et al., 2006). Nevertheless, previous studies also
identified a subgroup of melanomas lacking mutations
in NRAS and BRAF genes, for which it was speculated that
ERK activation occurs through previously unidentified effec-
tors (Rodolfo et al., 2004; Tsao et al., 2004; Goel et al.,
2006).
The Ras–PI3K–Akt pathway is an established regulator
of cell survival in many human cancers (Brunet et al., 1999;
Datta et al., 1999; Vivanco and Sawyers, 2002), with the
PIK3CA gene, the catalytic subunit of PI3K, being rarely
mutated in melanoma (Omholt et al., 2006). Activated,
phosphorylated, Akt (p-Akt) is present in melanoma (Dhawan
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et al., 2002; Li et al., 2003) but not in nevi (Dhawan et al.,
2002). Furthermore, higher expression of p-Akt correlated
with melanoma progression and worse patient survival
in melanomas with thickness p1.5mm (Dai et al., 2005).
In contrast to this finding, another publication associated
complete lack of nuclear expression of p-Akt with shorter
disease-free survival in patients with superficial-spreading
melanoma (Slipicevic et al., 2005). In relation to this path-
way, it has been found that loss of the PTEN protein, which
opposes the activity of PI3K (Maehama and Dixon, 1998),
in cooperation with mutated BRAF, is likely to be involved
in melanoma pathogenesis (Tsao et al., 2004).
We now report a study addressing the impact on survival
of NRAS and BRAF mutations and activation of Akt and
ERK in T1–2 primary cutaneous melanomas, in relation to
previously established clinicopathological factors.
RESULTS
NRAS/BRAF mutation frequency
In this investigation, we selected two groups of T1–2 primary
cutaneous melanomas, matched for tumor thickness, with
overall survival below or above 5 years, respectively. Primary
tumors from 57 patients were used in the study, and their
characteristics are shown in Table 1. Analysis of NRAS and
BRAF mutation status was performed using single-strand
conformation polymorphism (SSCP) and nucleotide sequence
analyses (Figure 1). Mutations in the NRAS gene were found
in 15 (26%) samples; 3 (5%) in exon 1 and 12 (21%) in
exon 2 (Table 2). One out of three mutations in exon 1 was a
missense mutation (G13D), whereas the two others were
silent (G12G, T20T). Of 12 mutations found in exon 2, 3 were
Q61R, 7 were Q61K, 1 was G60E, whereas 1 sample carried
both Q61R and Q61K mutations in different parts of the
tumor. BRAF exon 15 mutations were found in 22 (39%)
samples (Table 2); 20 were V600E, 1 was V600K, and another
was G596S. Furthermore, two samples harbored mutations in
both genes (NRAS/BRAF: Q61K/V600E). The overall mutation
frequency for both genes was 61% (35 samples).
Mutation status was analyzed with respect to patient
survival (Figure 2). Patients with BRAF-mutated tumors had
significantly worse survival than those with wild-type tumors
(P¼0.0219; Wilcoxon–Gehan exact life table test, pairwise
comparison). In contrast, survival of patients with NRAS-
mutated tumors was similar to patients with wild-type tumors
(P¼0.1300; Wilcoxon–Gehan exact life table test, pairwise
comparison).
Phosphorylated Akt expression
We were able to evaluate expression of p-Akt in 49 (86%)
samples using immunohistochemistry (Figure 3) based on an
immunohistochemical score (IRS) system (details in Materials
and Methods). When staining in cytoplasm and nucleus was
evaluated, all samples with nuclear staining also showed
cytoplasmic staining. Overall, cytoplasmic p-Akt was obser-
ved in 42 (86%) samples, and 23 of these also had nuclear
activation of Akt (Table 3). Additionally, significantly higher
cytoplasmic quantity score was found when compared to
nuclear score (Po0.001; Table S1a).
No significant differences in the total IRS values for p-Akt
were observed between subgroups with different mutation
status, although nearly all had significantly higher values in
cytoplasm than in nucleus (Table 4).
Higher nuclear IRS score (P¼ 0.045; Table S1a) was found
in the group that lived more than 5 years. Furthermore,
almost complete lack of nuclear activation of Akt was
observed in most of the samples from the short survival group
(Table S1b).
Table 1. Patient and tumor characteristics
Survival
More than 5
years
Less than 5
years Total
N (%) N (%) N (%)
Total number 42 15 57
Gender
Male 28 (67) 11 (73) 39 (68)
Female 14 (33) 4 (27) 18 (32)
Median age at diagnosis
(range)
54 (25–83) 63 (43–83) 57 (25–83)
Site
Head and neck 4 (10) 0 (0) 4 (7)
Trunk 16 (38) 9 (60) 25 (44)
Upper extremities 11 (26) 2 (13) 13 (23)
Lower extremities 11 (26) 4 (27) 15 (26)
Histology
Superficial spreading
melanoma
31 (74) 11 (73) 42 (74)
Nodular melanoma 6 (14) 1 (7) 7 (12)
Lentigo maligna melanoma 1 (2) 0 (0) 1 (2)
Acral lentiginous
melanoma
0 (0) 1 (7) 1 (2)
Unclassifiable melanoma 4 (10) 2 (13) 6 (10)
Clark
II 6 (14) 0 (0) 6 (10)
III 28 (67) 12 (80) 40 (70)
IV 8 (19) 2 (13) 10 (18)
V 0 (0) 1 (7) 1 (2)
Mean tumor thickness in
mm (range)
1.3 (0.8–2.0) 1.4 (0.8–2.0) 1.3 (0.8–2.0)
Ulceration
Present 7 (17) 9 (60) 16 (28)1
Absent 35 (83) 6 (40) 41 (72)1
1P=0.003 (Fisher’s two-sided exact test showed difference in frequency).
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Phosphorylated ERK expression
We were able to evaluate 46 (81%) samples for phosphory-
lated ERK (p-ERK) expression using immunohistochemistry
(Figure 3). Cytoplasmic and nuclear p-ERK was observed
in 38 (83%) and 32 (70%) samples, respectively (Table 3)
with 31 (67%) showing activated ERK in both cellular
compartments.
Overall, total cytoplasmic IRS values of p-ERK were
lower than total nuclear IRS values (Table 4). Tumors
with NRAS exon 2 mutations had higher cytoplasmic
and nuclear p-ERK IRS values than BRAF-mutated tumors
as well as higher nuclear IRS than wild-type tumors
(Table 4).
The group that lived more than 5 years had significantly
higher number of cases with activated cytoplasmic ERK
(P¼0.02; Table 3) as well as higher cytoplasmic and nuclear
IRS values than the poor survival group (Table S1c).
1 2 3 4
1 2 3
Figure 1. Examples of NRAS and BRAF mutation analyses in primary
melanomas. (a–c) NRAS exon 2 and (d–f) BRAF exon 15 mutation analyses.
(a) SSCP lanes 1–2, wild-type samples; lanes 3–4, NRAS Q61K mutation
samples. (b) Wild-type sequencing graph (codons 61–63); (c) sequencing
graph with Q61K mutation. (d) SSCP lane 1, wild-type sample; lanes 2–3:
BRAF V600E mutation samples. (e) Wild-type sequencing graph (codons
600–601); (f) sequencing graph with V600E mutation. Arrows, bands
harboring mutations.
Table 2. Mutation status
Survival
More than 5 years Less than 5 years Total
Number of
samples (%)
Mutation (number
of samples)
Number of
samples (%)
Mutation (number of
samples)
Number of
samples (%)
Total number 42 15 57
NRAS mutations
Exon 1 3 (7) G13D (1), G12G (1), T20T (1) 0 (0) 3 (5)
Exon 2 7 (17) Q61R (3), Q61K (3), Q61R/
Q61K (1)1
5 (33) Q61K (4), G60E (1) 12 (21)
BRAF mutations
Exon 15 12 (29)2 V600E (10), V600K (1),
G596S (1)
10 (67)2 V600E (10) 22 (39)
Total 22 (52) 13 (87)3 35 (61)
1Each mutation was independently found in extracts from two different parts of the tumor.
2P=0.014 (Fisher’s two-sided exact test showed difference in frequency).
3Two samples harbored mutations in both genes (NRAS/BRAF: Q61K/V600E).
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Figure 2. Overall survival, Kaplan–Meier and Wilcoxon–Gehan exact life
table tests (overall comparison between the groups), according to the
mutation status. Wild type, no mutations in NRAS/BRAF; NRAS mutant,
mutations in NRAS; BRAF mutant, mutations in BRAF. Diamonds represent
censored cases.
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Univariate and multivariate survival analyses
We analyzed the impact on survival of the patient and tumor
parameters listed in Table 1 and no significant correlation
was observed except for the presence of ulceration, which
was associated with short survival (P¼ 0.001; Figure 4a).
Of the novel factors investigated in our study, the presence
of BRAF exon 15 mutations (P¼0.005; Figure 4b)
and the absence of nuclear activation of Akt (P¼0.022;
Figure 4c) and of cytoplasmic activation of ERK (P¼0.003;
Figure 4d) were significant prognostic predictors of short
survival.
a b c d
e f g h
Figure 3. Immunohistochemical scoring of p-Akt and p-ERK (original magnification 500). First row, cytoplasmic intensity score (ISc) and nuclear
intensity score (ISn) of p-Akt: (a) ISc¼0, ISn¼0; (b) ISc¼ 2, ISn¼ 1; (c) ISc¼ 2, ISn¼ 2; (d) ISc¼3, ISn¼3. Second row, cytoplasmic intensity score (ISc) and
nuclear intensity score (ISn) of p-ERK: (e) ISc¼ 0, ISn¼ 0; (f) ISc¼ 1, ISn¼ 1; (g) ISc¼ 2, ISn¼ 2; (h) ISc¼ 2, ISn¼3. Bar¼ 50 mm.
Table 3. Activation of phosphorylated Akt and ERK
Survival
More than 5 years (%) Less than 5 years (%) Total
Akt (number of
samples)
36 13 49
Cytoplasmic
Absent 5 (14) 2 (15) 7
Present 31 (86) 11 (85) 42
Nuclear
Absent 16 (44) 10 (77) 26
Present 20 (56) 3 (23) 23
ERK (number
of samples)
34 12 46
Cytoplasmic
Absent 3 (9)1 5 (42)1 8
Present 31 (91)1 7 (58)1 38
Nuclear
Absent 9 (26) 5 (42) 14
Present 25 (74) 7 (58) 32
1P=0.02 (Fisher’s two-sided exact test showed difference in frequency).
Table 4. Immunohistochemical (IRS) scoring of p-Akt
and p-ERK1
Overall WT2 NRAS exon 2 BRAF exon 15
p-Akt (number
of samples)
49 19 8 17
Cytoplasm 5.03,9 4.54,9 5.8 4.65,9
Nucleus 2.13,9 2.14,9 3.0 1.25,9
p-ERK
(number of
samples)
46 17 8 16
Cytoplasm 4.1 3.9 6.96,9 2.96,9
Nucleus 5.5 5.07,9 8.57,8,9 4.28,9
1Excluding 3 samples with NRAS exon 1 alterations and 2 samples
harboring simultaneous mutations in NRAS and BRAF.
2wt – wild type for NRAS and BRAF.
3Po0.001.
4P=0.005 (not significant after Bonferroni correction).
5P=0.002.
6P=0.020 (not significant after Bonferroni correction).
7P=0.049 (not significant after Bonferroni correction).
8P=0.032 (not significant after Bonferroni correction).
9Mann–Whitney U-test showed differences between covariates.
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Interestingly, the impact of tumor ulceration differed in
BRAF-mutated versus wild-type tumors. In patients with
BRAF exon 15 mutations, presence of ulceration had an
impact on survival (P¼ 0.001; Figure 4f), whereas there
was no effect of ulceration on survival in tumors without
BRAF mutations (Figure 4e).
A univariate Cox regression analysis confirmed the
significance of absence of cytoplasmic activation of ERK,
presence of tumor ulceration, presence of BRAF exon 15
mutation, and absence of nuclear activation of Akt as markers
for poor survival (Table 5). In the multivariate analysis, the
significant independent prognostic factors were absence of
cytoplasmic activation of ERK and presence of ulceration
(P¼0.007 and P¼0.008, respectively), whereas presence of
BRAF mutation showed a nonsignificant trend, P¼ 0.066, and
nuclear activation of Akt lost its prognostic impact (Table 5).
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Figure 4. Analyses of overall survival in relation to tumor characteristics. Overall survival, Kaplan–Meier and Wilcoxon–Gehan exact life table tests,
according to: (a) ulceration; (b) BRAF exon 15 mutation; (c) nuclear activation of Akt; (d) cytoplasmic activation of ERK. Overall survival according to ulceration
and BRAF exon 15 mutation status: (e) BRAF wild type; (f) BRAF mutant. Diamonds represent censored cases.
Table 5. Univariate and multivariate Cox proportional
hazard regression analysis of overall survival
Univariate Multivariate
Covariate Wald statistic Probability Wald statistic Probability
Absence of
cytoplasmic
p-ERK
11.51 P=0.001 7.15 P=0.007
Presence of
ulceration
7.73 P=0.005 7.06 P=0.008
Presence of BRAF
exon 15 mutation
6.32 P=0.012 3.37 P=0.066
Absence of
nuclear p-Akt
3.90 P=0.048 0.08 NS
NS, not significant.
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DISCUSSION
In this study, we focused on the commonly mutated NRAS/
BRAF genes and downstream-activated proteins of the
Ras–Raf–MEK–ERK and Ras–PI3K–Akt pathways to investigate
the frequency of their activation and the correlation to overall
survival in primary cutaneous melanomas. To our knowl-
edge, this is the first study that simultaneously analyzed
activation of both these two pathways in clinical melanoma
samples.
NRAS mutations in our data set did not correlate with
overall survival. Moreover, we noticed that total cytoplasmic
and nuclear p-ERK and p-Akt IRS values of the NRAS exon
2-mutated subgroup were higher when compared with the
wild-type or BRAF-mutated subgroups, indicating intense
activation by oncogenic NRAS of both the Raf–MEK–ERK and
the PI3K–Akt pathways.
BRAF mutations have been reported at a high frequency in
nevi and melanomas, but there is still insufficient knowledge
about their importance in melanoma development and
progression. In a majority of publications, alterations in this
gene have not been shown to be correlated to survival
(Kumar et al., 2003a; Houben et al., 2004; Shinozaki et al.,
2004). In our study, we found an overall BRAF exon 15
mutation frequency of 39% with a significant twofold higher
occurrence in the group that lived less than 5 years. In
agreement with previous reports in melanoma, 95% of the
mutations were V600E alterations.
We identified a trend toward an overall correlation
between presence of ulceration and BRAF exon 15 mutations
(P¼0.090), with a significant association for the group that
lived less than 5 years (P¼0.024). Interestingly, impact of
ulceration on survival was limited to patients with BRAF
mutations, whereas ulceration had no effect on tumors
without BRAF mutations (Figure 4e and f). This interaction
between BRAF mutations and ulceration has, to our knowl-
edge, not been previously described and should be further
investigated. As ulceration is a necrotic process, we specu-
lated that it may be associated with the programmed necrotic
cell death pathway (Papucci et al., 2004) where c-Myc, a
downstream effector of B-Raf, plays a key role. Interestingly,
several reports correlate overexpression of c-Myc to worse
melanoma outcome (Kraehn et al., 2001; Grover et al.,
2003).
Unexpectedly, we found two primary melanomas to carry
mutations in both NRAS and BRAF (4% of total). This is in
contrast to previous studies by us (Omholt et al., 2003) and
others (Davies et al., 2002; Thomas et al., 2007) on metastatic
and primary melanomas where such mutations have been
reported to be mutually exclusive. Our results indicate that
T1–2 melanomas may in some instances be polyclonal, with
separate tumor cell clones carrying mutations in NRAS and
BRAF, respectively. It is conceivable that during further tumor
progression, one tumor cell clone will expand and ‘‘take
over’’ the progressing tumor, leading to the pattern of
mutually exclusive NRAS/BRAF mutations.
We noticed that total cytoplasmic and nuclear p-ERK IRS
values in the BRAF subgroup were lower than in the wild-
type and NRAS-mutated subgroups, suggesting that mutated
BRAF has a relatively low potential to activate ERK. This
agrees with a report that mutated B-Raf shows a 50-fold lower
activation of ERK than mutant Ras (Davies et al., 2002), but
leaves room for speculation regarding the mechanism of ERK
activation in the wild-type subgroup. An obvious possibility
would be that the Ras–Raf–MEK–ERK pathway is activated
by tyrosine kinase receptors upstream of Ras, such as the
epidermal growth factor receptor, fibroblast growth factor
receptor, or c-kit.
One of our major findings was that the overall cytoplasmic
and nuclear IRS values of p-ERK were lower in the group that
lived less than 5 years. In addition, a multivariate analysis
showed that absence of cytoplasmic activation of ERK was a
significant independent adverse prognostic marker, opposing
previous results that showed no impact of p-ERK expression
on survival (Jorgensen et al., 2003; Zhuang et al., 2005).
As the antibody used in our study does not distinguish
between the different ERK isoforms (ERK1 and ERK2), we may
speculate that these different observations might be explained
with opposing functions of the two different ERK kinases. This
has been recently evaluated in several nonmelanoma models
where ras-induced proliferation has been associated with
ERK2 expression, whereas ERK1 has been proposed to play a
regulatory role by antagonizing ERK2 activity (Vantaggiato
et al., 2006; Fremin et al., 2007). We can hypothesize that
the inhibitory ERK1 isoform may be more activated in our
samples. However, the existence of additional pathways in
melanoma pathogenesis, which do not involve ERK activa-
tion, might also be a plausible explanation for the worse
prognosis in patients whose tumors lack cytoplasmic ERK
activation. Interestingly, the importance of absence of ERK
activation in cancer progression has been previously reported
in prostate cancer (Paweletz et al., 2001). More recently,
a melanoma subtype with epithelial characteristics, which
lacks ERK activation, has been proposed (Shields et al.,
2007). Moreover, melanomas lacking activation of Ras–Raf–-
MEK–ERK pathway, but exhibiting increased copy numbers of
downstream genes such as CDK4 and CCND1, have been
described (Curtin et al., 2005). It is possible that the
melanomas with a poor outcome and lacking cytoplasmic
p-ERK expression in our series have characteristics similar to
these types of melanomas.
Additionally, almost complete lack of nuclear Akt activa-
tion in our poor melanoma survivor group is in agreement
with a previously published report (Slipicevic et al., 2005)
that correlated complete lack of nuclear expression of p-Akt
with shorter melanoma disease-free survival. This opposes an
earlier report that linked higher activation of Akt to worse
melanoma survival, although these investigators did not
report on cellular sublocalization of p-Akt (Dai et al., 2005).
The main active Akt isoform in melanomas is Akt3, of which
increased expression has been related to melanoma progres-
sion (Stahl et al., 2004). As the antibody we used does not
distinguish between Akt isoforms, it is possible that the lack of
nuclear p-Akt does not involve a reduction of Akt3 activation.
In conclusion, lack of cytoplasmic p-ERK and presence
of ulceration were independent unfavorable prognostic
markers in melanoma patients with T1–2 primary cutaneous
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melanomas. Although BRAF exon 15 mutations were not an
independent prognostic factor in the overall analysis, there
was an interaction between ulceration and BRAF exon 15
mutations. This was manifested by the observation that
ulceration was of prognostic importance only in BRAF-
mutant tumors, whereas ulceration had no adverse effect in
tumors lacking mutant BRAF. Our results suggest that
cytoplasmic immunohistochemical score of p-ERK could be
used as a prognostic marker for T1–2 melanoma survival,
although larger confirmatory studies are warranted.
MATERIALS AND METHODS
Patients and biopsy samples
For this study, we selected patients with primary cutaneous
melanomas with different clinical outcome from the Stockholm–
Gotland Regional Melanoma Registry. The 57 melanomas were
T1–2 tumors (with tumor thickness p2mm) and were selected to
represent two distinct groups differing in overall survival: 42 (74%)
patients who lived more than 5 years and 15 (26%) who survived
less than 5 years after diagnosis of primary tumor (Table 1). The two
groups were matched for tumor thickness. The patients underwent
surgical excision of primary melanoma between 1977 and 1995. All
biopsy samples were formalin-fixed, paraffin-embedded tissue
blocks. As around half of the patients were dead at the time when
the study was performed, informed consents could not be obtained.
The Ethics Committee of the Karolinska Institutet approved the study.
The study was conducted according to the Declaration of Helsinki
Principles.
Overall, there were no significant differences in clinical and
histopathological parameters between the groups (Table 1), except
for a higher ulceration frequency in the short survival group
(P¼ 0.003). Thirty-two (56%) patients were still alive at the time of
analysis, whereas 25 (44%) had died. Median survival for both
groups combined was 284 months, with median survival not
reached at the time of analysis for the group that lived more than
5 years (range 75–349þ ) and 21 months (range: 5–55) for the poor
survival group.
DNA extraction
From each paraffin-embedded biopsy sample, four serial 6 mm
sections were cut. One of the inner sections was counterstained with
hematoxylin and eosin as a guide for dissection, whereas the other
three sections were used for microdissection with a PixCell
laser-capture microscope (Arcturus Engineering, Mountain View,
CA). Depending on the number of collected cells (up to around 500),
dissected sections were incubated in 30–40 ml of lysis buffer
(50 mgml1 proteinase K (Boehringer Mannheim, Germany), 10mM
Tris (pH 8.3), 1mM EDTA, and 0.5% Tween 20) at 561C, overnight.
Proteinase K was inactivated by incubating the samples at 951C for
10minutes.
The HT1080 and the 224 cell lines, carrying a Q61K (C181A)
and Q61R (A182G) substitutions, respectively, were used as
positive controls for NRAS exon 2 mutations. As a positive control
for the BRAF exon 15 mutations, A375 cell line was used, which
carries a V600E (T1799A) substitution. DNA from these cell
lines was extracted using the Wizard Genomic DNA Purification
Kit (Promega, Madison, WI) according to the manufacturer’s
instructions.
Mutation analyses
Polymerase chain reaction amplification, SSCP, and nucleotide
sequence analyses for BRAF exon 15 and NRAS exon 2 were carried
out as described previously (Omholt et al., 2002, 2003). NRAS exon
1 PCR amplification was performed as described previously
(Eskandarpour et al., 2003), with a minor modification regarding
temperatures and number of cycles (Table S1e). Samples for SSCP
were separated on 7.5% nondenaturing polyacrylamide gels with
(for NRAS) and without glycerol (for BRAF). After electrophoresis,
the gels were dried and exposed to autoradiographic film for
14–24hours. Aberrant bands were excised from the dried gels,
reamplified, and purified using QIAquick Gel Extraction Kit (Qiagen,
Hilden, Germany). Afterward, nucleotide sequence analyses were
carried out using the BigDye Terminator Cycle Sequencing
Ready Reaction kit (Applied Biosystems, Foster City, CA) and an
ABI PRISM 310 Genetic Analyzer (Applied Biosystems). Sequence
analyses were performed in both directions, using the nested
primers as sequencing primers. Mutations were confirmed by two
independent PCR/SSCP analyses.
Immunohistochemical studies
Immunohistochemistry was performed on formalin-fixed paraffin-
embedded sections using a rabbit anti-phospho-Akt (Ser473)
antibody (1:65; Cell Signaling Technology, Danvers, MA) and
anti-phospho-p44/42 mitogen-activated protein kinase (Thr202/
Tyr204) antibody (1:50; Cell Signaling Technology, Danvers,
MA) as described previously (Omholt et al., 2006). Negative controls
were performed by omitting the primary antibody.
Staining percentage was based on estimated number of melano-
ma cells that were positively stained either in cytoplasm or nucleus
over the whole tumor area, in every tissue section. In the majority of
cases, the staining was homogenous, and when it was hetero-
geneous, we report the staining representative of the largest area of
the section. Quantity score was calculated in the following manner:
0 (0–5% of stained tumor cells); 1 (6–25%); 2 (26–50%); 3 (51–75%);
and 4 (76–100%). Intensity score was rated as: 0, no staining;
1, mild; 2, moderate, and 3, strong staining. IRS (Remmele and
Stegner, 1987; Remmele and Schicketanz, 1993; Bloomer et al.,
2003; Zhuang et al., 2005) was calculated by multiplying the
quantity score with the intensity score and may range from 0 to 12.
Three observers, without knowledge of patients’ outcome, indepen-
dently analyzed all sections (B.J., D.K., S.E.), and differences in
overall interpretations were resolved in a joint session (a minority
of all samples).
Statistical analysis
Statistical analyses were performed with Microsoft Excel 2000
(Microsoft Corporation, Redmond, WA) and SPSS version 14.0
software (SPSS Inc., Chicago, IL). The Fisher’s exact test was used to
compare distributions between groups, whereas the Mann–Whitney
U-test was used for assessing whether two samples of observations
came from the same distribution. Additionally, Wilcoxon signed-
ranks test compared the differences of two related measurements on
a single sample. Spearman’s rank correlation test was used to
calculate relationships between two variables. Kaplan–Meier,
Wilcoxon (Gehan) exact life table and log-rank tests were used to
compare overall survival between groups. Multivariate analysis to
determine prognostic value of covariates regarding overall survival
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was performed using the Cox regression model. All analyses were
two-tailed and a P-value of less than 0.05 was considered as
significant.
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